Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
This research study aims to explore the combination of two targeted drugs as first-line treatment for Non-Small Cell Lung Cancer (NSCLC) with uncommon EGFR mutation.
Non-small Cell Lung Cancer Metastatic|EGFR G719X|EGFR L861Q|EGFR S768I
DRUG: Icotinib|DRUG: Befotertinib
Objective Response Rate （ORR）, ORR, per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR)., 24 months
Progression-free survival（PFS）, PFS, defined as time from study drug administration to progression or death due to any cause., 12 months|Disease control rate（DCR）, DCR, defined as proportion of complete response, partial response, and disease stabilization to the proportion of patients with evalueable tumors., 12 months|Overall survival （OS）, OS, defined as the time from study drug administration until the date of death due to any cause., 24 months
This research study aims to explore the combination of two targeted drugs as first-line treatment for Non-Small Cell Lung Cancer (NSCLC) with uncommon EGFR mutation.